CD8A and cancer: The results revealed that when BMDC were treated with CpG, COVA, or their combination, in their soluble form or coupled to MNP, CD8+ OT-I T cells activation resulted in a reduction of B16-OVA cell viability that was dependent on the number of cancer cells.